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Abstract
Background: This study aimed to evaluate the effectiveness of gancyclovir (GCV) treatment for severe
cytomegalovirus (CMV)-associated pneumonia in immunocompetent children.
Method: We enrolled patients with CMV-associated severe pneumonia admitted to the Vietnam National Hospital
of Pediatrics, Hanoi, Vietnam, from January 2010 to December 2011. On admission, though respiratory bacteria and
viruses were not detected in tracheal aspirates, more than 5 × 103 copies/mL of CMV-DNA were detected in both
tracheal aspirates and in blood plasma. GCV was given intravenously at a dose of 10 mg/kg/24 h for a duration of
14 days at most. The dose was then reduced to 5 mg/kg/24 h until CMV-DNA was not detected in plasma. The
main study variables included clinical symptoms, complete blood count, hepatic and renal function, chest X-ray,
CMV viral load, duration of GCV treatment and outcome.
Results: Forty-three patients were enrolled in the study. The median age of patients was 57 (interquartile range [IQR]
45–85) days. Clinical and laboratory findings included anemia (67.4%), leukocytosis (90.7%), hepatosplenomegaly (60.5%),
elevated liver enzymes (74.4%), decreased ratio of CD4: CD8-positive T lymphocytes (69.4%), and decreased serum IgG
concentration (25.7%). The median duration of GCV treatment was 12 days (IQR 7-21). Thirty-seven patients (86.0%)
showed normal chest X-rays at the end of treatment. One infant died (2.3%); the other children (97.7%) were discharged
in good condition. There was no severe toxicity associated with GCV treatment.
Conclusion: GCV is safe and effective for the treatment of severe CMV-associated pneumonia in children.
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Background
Cytomegalovirus (CMV) is a common cause of acute
lower respiratory infection, particularly in immunocom-
promised hosts, and is associated with high mortality
[1-3]. While CMV infection in immunocompetent indi-
viduals has traditionally been considered a benign and
self-limited disease, a few studies have reported the clin-
ical manifestations and treatment of CMV infection
among immunocompetent patients [4-8]. However, little
is known about the clinical and laboratory features and
CMV-associated pneumonia in children who are not
immunocompromised.
The aim of the present study was to evaluate the ef-
fectiveness of GCV in severe CMV-associated pneumo-
nia treatment in children.
Methods
Patients and case definitions
This study was carried out from January 2010 to
December 2011 at the Vietnam National Hospital of
Pediatrics, Hanoi, Vietnam. All children with pneumonia
who met the following inclusion criteria for CMV-
associated pneumonia were enrolled in the study: (1) severe
pneumonia based on WHO criteria (in infants <2 months
old, severe chest in-drawing or a respiratory rate >60 per
minute; in children ≥2 months–5 years, chest in-drawing
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[9]), (2) CMV-DNA detected in tracheal aspirates and
blood plasma specimens with more than 5 × 103 copies/mL
[10], (3) not have specific immunocompromised status such
as HIV infection, post-transplantation, known immunosup-
pressive disorder or prior chemotherapy, (4) no co-
infection with bacteria or viruses other than CMV, and (5)
consent from parents or legal guardian to participate in the
study.
Assessment of immune status
The immune status of the patients was assessed by the
percentage of CD4-positive T lymphocytes for cellular
immunity and serum IgG concentration for humoral im-
munity. In this study, when CD4 cells were <35% of total
lymphocytes the CD4 percentage was considered low
[11] and less than 176 mg/dL of IgG was defined as low
serum IgG [12].
Detection of viruses and bacteria
Tracheal aspirates were taken on admission from all
patients for bacterial culture, including a rapid test for
respiratory syncytial virus (RSV), influenza virus type A
(FluA) and type B (FluB) (Standard Diagnostics, Korea)
and RT-PCR for adenovirus (AdV) (Qiagen, Germany)
and human rhinovirus (HRV) (Qiagen, Germany). CMV-
DNA as detected from both tracheal aspirates and blood
plasma using the real-time PCR method. The tracheal
aspirates and EDTA-treated blood samples collected in
the Respiratory Department were transferred to the
Molecular Biology Laboratory, Microbiology Department,
NHP. Tracheal aspirates and plasma specimens were stored
at −70°C until tested.
Nucleic acid was extracted from 100 μL of each speci-
men by MagNAPure LC 2.0 robot (Roche Molecular
Systems, Mannheim, Germany). The PCR amplification
was performed in a total volume of 25 μL in the
presence of TaqMan Universal PCR master mix (2X)
(Qiagen, TaqMan MGB Probe, Germany), with each
primer and TaqMan probe. PCR was performed with the
IQ5 real-time PCR system (Bio-Rad, Hercules, CA)
under the following conditions: 2 minutes at 46°C, 10 mi-
nutes at 95°C, 45 cycles of 95°C for 15 seconds and 58°C
for 1 minute [13].
Treatment
Children whose percutaneous oxygen saturation level
was less than 92% received oxygen supplementation via
facemask or nasal prongs. After taking the samples for
bacterial culture, the patients were given 3rd or 4th
generation cephalosporin antibiotics. After obtaining the
disgnosis of CMV-associated pneumonia, we stopped the
antibiotics and started anti-CMV treatment. All enrolled
children were given ganciclovir (GCV) (Cymevene,
manufactured by Roche, Germany) intravenously at a dose
of 10 mg/kg/24 h for a duration of 14 days at most,
followed by 5 mg/kg/24 h for 7 days or until CMV-DNA
was not detected in blood plasma [14]. Intravenous im-
munoglobulin (IVIG) was given when the patients had low
humoral immunity status. Clinical signs and symptoms
were assessed daily. Complete blood count (CBC), hepatic
and renal function, chest X-ray and CMV viral load were
checked before the commencement of GCV treatment and
then every 7 days until discharge. Treatment was consid-
ered successful if the patient no longer had respiratory
symptoms and CMV-DNA in plasma was under the detec-
tion limit (<100 copies/mL).
Statistical analysis
Data were entered into Epidata 3.1 (EpiData Association,
Odense, Denmark), and then transferred into SPSS 10.0
(IBM SPSS, Armonk, NY, USA) for analysis. Continuous
variables were tested for normal distribution with the
Shapiro-Wilk statistic. Continuous variables were expressed
as means +/− standard deviations for normally distributed
variables or medians and interquartile ranges (IQR) for
non-normally distributed variables. P < 0.05 was considered
statistically significant.
Ethical considerations
The Ethical Committee of the NHP approved the study.
Written informed consent was obtained from the par-
ents or legal guardians of the patients.
Consent
Written informed consent was obtained from the par-
ents for publication of the X-ray (Figure 1).
Results
Patient profiles
During the study period, we enrolled 43 patients. The
median age on admission was 57 (IQR 45–85) days.
Twenty-six patients were boys (60.5%) and 17 (39.5%)
were girls. In our study, 26 (60.5%) patients were the
firstborn, 36 (83.7%) were born by vaginal delivery, 23
(53.5%) were exclusively breastfed and 25 (58.1%) were
term infants.
The time interval between onset and admission was
more than 7 days for 39 (90.7%) patients. Table 1 shows
the main clinical and laboratory characteristics of the pa-
tients. Twenty-nine patients had anemia (Hb <11 g/dL)
(67.4%) and 26 patients had hepatosplenomegaly on ad-
mission (60.5%). Thirty-nine patients had leukocytosis
(>10,000/mm3) (90.7%), with mainly lymphocytes. Im-
mune status was investigated in 36 patients. A low CD4
percentage (<35%) of T lymphocytes was observed in 25
of 36 (69.4%) patients and low serum IgG (<176 mg/dL)
was observed in 9 of 35 (25.7%) patients. CMV-IgG was
positive in all patients and CMV-IgM was positive in 29
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(67.4%). The median CMV viral load in plasma was 59.5
(IQR 30–160) × 103 copies/mL, whereas that in tracheal
aspirate specimens was 120 (IQR, 7–400) × 103 copies/
mL on admission. The chest X-ray taken on admission
showed interstitial infiltrate changes in 28 patients
(65.1%). Twenty patients (46.5%) had combination inter-
stitial and consolidation images. Only 5 (11.6%) patients
had consolidation images.
Results for risk factors
We conducted subanalyses of risk factors for term versus
pre-term infants, low-birth-weight versus normal-birth-
weight infants, vaginal delivery versus cesarean delivery in-
fants, and breastfed versus not breastfed infants. There
were no differences in the viral load improvement between
these subgroups (P > 0.05).
Characteristics for each age group
The median length of hospitalization was 23 (IQR 18–
37) days. The median duration of GCV treatment and
oxygen treatment were 12 (IQR 7–21) days and 10 (IQR
3–19) days, respectively. The patients were divided into
three groups according to their age: 30–60 days, 61–
90 days and >90 days. There were imbalances in the
number of patients in the age groups. The characteristics
in each group are shown in Table 2. Twenty-five patients
(58.1%) were 30–60 days old. The median value of CMV
viral load in plasma was highest in the youngest group
(30–60 days). The duration of GCV treatment decreased
with increasing age (P < 0.05). The duration of both
GCV treatment and oxygen treatment were higher in
the oldest group (>90 days). As for immune status, a low
CD4 percentage was observed in 81% of the youngest
group (30–60 days).
Clinical symptoms and laboratory data
After GCV treatment had started, fever decreased to a
normal range within 2.5 (IQR 2–5) days and cough
reduced within 5 (IQR 2–7) days. On admission, 29 pa-
tients had Hb levels under 11 g/dL. Only one patient
needed a blood transfusion because the Hb level de-
creased from 9.2 g/dL to less than 8 g/dL. The anemia
in these patients improved after GCV treatment.
Thirty-nine patients had an elevated count on admis-
sion, which decreased gradually to within the normal
range. No patient had a WBC decrease below the nor-
mal range (Table 3). Concentrations of liver enzymes
(AST and ALT) were slightly elevated in 32 patients on
admission. Though the concentrations of both en-
zymes increased transiently in 10 patients after 1 week
of treatment, they returned to the same levels as before
treatment at the end of treatment (Table 3). During
antiviral therapy, platelet counts, renal function
and electrolytes were in the normal range. In the
subanalysis there were no significant differences in
WBC count or concentration of AST and ALT changes
between the subgroups (P > 0.05).
CMV viral load
The median level of CMV viral load on admission was
334.7 ± 331.9 × 103 copies/mL. Plasma CMV viral load
declined rapidly after starting GCV treatment. After the
first week, CMV-DNA fell under the detection limit
(UDL) in 23 (53.5%) patients. These data were statisti-
cally significant with P < 0.05. CMV-DNA were UDL in
14 (32.6%) additional children at the end of the second
week and in the 4 (9.3%) remaining children at the end
of the third week. The decline of plasma CMV viral load
is shown in Figure 2.
Chest X-ray
The chest X-ray images improved with GCV treatment
(Figure 1). After the GCV treatment, 37 patients (86.0%)
showed a normal chest X-ray. As for the other 6 pa-
tients, a few lesions persisted on the chest X-ray on
discharge, though they improved clinically as CMV-
DNA became undetectable. Follow-up chest X-rays
1 month after discharge were normal.
a b
Figure 1 Representative chest X-ray findings before and after treatment. (a) X-ray on admission before treatment. (b) X-ray on day 14 of
GCV treatment.
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Outcome
Forty-two of 43 patients (97.7%) were cured and healthy
when discharged. One patient acquired Burkholderia
cepacia and developed respiratory failure and multiorgan
failure, and died.
Discussion
In this report, we present the clinical and laboratory fea-
tures of and the effect of antiviral treatment on CMV-
associated pneumonia in apart children without specific
immunocompromised status such as HIV infection,
post-transplantation, known immunosuppressive dis-
order or prior chemotherapy. Most of our patients were
born by vaginal delivery, exclusively or partly breastfed
and were term infants, but there were no statistically sig-
nificant differences in changes in viral load between
these subgroups of patients (P > 0.05). In Figure 2, there
were four patients who had an increase in plasma viral
load after one week of GCV treatment, but they were
negative at the end of the second week. They were all fe-
male, of normal birth weight, full term, and exclusively
breastfed. Two patients were delivered vaginally. We
presume patients acquired infection after birth and in-
fection progressed naturally. A limitation of our study is
that it is difficult to know when the patients were ex-
posed to CMV (for example, by intrauterine infection,
vaginal infection, or breastfeeding). All developed symp-
toms of pneumonia after 30 days of birth so we con-
cluded that they acquired CMV infection after birth
because postnatal CMV pneumonia develops 4–8 weeks
after birth [14]. Numazaki et al. [15] and Jim et al. [16]
showed that a high human CMV viral load and
prolonged virus excretion in breast milk were maternal
risk factors for viral transmission to very low-birth-
weight infants.
It was remarkable that 67.4% of our patients had
anemia with a Hb level less than 11 g/dL and 60.5% had
hepatosplenomegaly on admission (Table 1). These char-
acteristics are not commonly seen in cases of pneumonia
because of other causes. Our findings were consistent
with Avila-Agüero et al., who showed 100% of patients
had anemia and 82% had hepatomegaly [7] and who
were also reported to have active CMV infection based
on standard criteria [14]. In addition to this, 90.7% of
Table 1 Clinical and laboratory information of the
patients in this study
Number Percentage





Low birth weight (< 2,500 g) 16 37.2%
First-child 26 60.5%
Exclusive Breast fed 23 53.5%
Blood transfusion history 5 11.6%
Vaginal delivery 36 83.7%
Term infants (gestational age ≥38 weeks) 25 58.1%
Symptoms







Body temperature ≥380C 23 58.5%
Sp02 <90% on room air 32 74.4%
Hepatomegaly 26 60.5%
Laboratory test
CRP <0.6 mg/dl 36 83.7%
Hemoglobin <11 g/dl 29 67.4%
Leukocytosis >10,000 leukocyte /mm3 39 90.7%
Aspartate aminotransferase (AST) > 40 IU/L 32 74.4%
Alanine aminotransferase (ALT) >37 IU/L 19 41.2%
Immunological data
Positive for CMV-IgM 29 67.4%
Positive for CMV-IgG 43 100%
Low CD4 (<35% of T cell )* 25/36 69.4%
Low IgG level (<176 mg/dl)** 9/35 25.7%
CMV viral load
CMV-DNA copies/mL in plasma,
Median (IQR), 103 copies/mL
59.5
(30-160)
CMV-DNA copies/mL in tracheal aspirates,




Interstitial changes 28 65.1%
Interstitial and consolidation 20 46.5%
Consolidation 5 11.6%
Table 1 Clinical and laboratory information of the
patients in this study (Continued)
Time interval between onset and visit





IQR Interquartile range, CMV cytomegalovirus, *Data were available for 36
patients.**Data were available for 35 patients.
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patients had leukocytosis, mainly lymphocytosis, which
was consistent with the study by Capulong et al. [2].
Generally, in cases of viral pneumonia, the number of
WBCs in blood is normal or decreased.
The main finding from chest X-rays was severe bilat-
eral interstitial change, which is one of the characteris-
tics of interstitial pneumonia including CMV pneumonia
[17]. However, it was impossible to diagnose CMV pneu-
monia solely based on by the chest X-ray findings. Be-
cause of limitations in our laboratory facilities, it was
also difficult to exclude other respiratory viruses, such as
influenza, parainfluenza, adenovirus, enterovirus, and
human metapneumovirus, which also cause interstitial
pneumonia.
It has been the consensus among researchers around
the world that CMV infection is an opportunistic infec-
tion and CMV disease occurs primarily in immunocom-
promised patients. Generally, CMV infection is an
inapparent infection for an immunocompetent patient.
However, all patients in this study were apparently im-
munocompetent. The immune statuses of 36 patients
(83.7%) were investigated. The levels of IgG decreased in
9 of 35 (25.7%) and the percentage of CD4-positive T
cells decreased in 25 of 36 (69.4%) patients. As shown in
Table 2, there was an imbalance in the number of pa-
tients in age groups and 81% of the patients 30–60 days
old showed a low immune status with a low CD4
percentage according to the pediatric test reference
value of the Mayo Clinic (P = 0.001) [11]. Those patients
also had a longer GCV treatment duration (P = 0.013),
and low IgG level (P = 0.02). One hypothesis to explain
the smaller number of patients older than 90 days would
be that as children grow, the immune system matures
enough to protect them from CMV infection. The de-
creases observed were not so severe as to suggest con-
genital immunodeficiency. If they had severe congenital
immunodeficiency, there would be more complications,
with other opportunistic infections. Though other reflec-
tions of immune status such as natural killer cell activity
should be examined, we suspected that other immune
system problems were temporary, but related to the de-
velopment CMV infection and pneumonia.
In our study, the CMV viral load in tracheal aspirate
specimens on admission was higher than that in plasma
specimens, which has been also reported in other studies
Table 2 Characteristics of the patients in each age-group
Age group 30-60 days 61-90 days >90 days P
Number of patients (male/female) 25(15/10) 11(7/4) 7(4/3)





CMV copies/mL in tracheal aspirates, Median (IQR) 66.9(5-396)x 103 copies/mL 185(122-900) x 103 copies/mL 212(15-410) x 103
copies/mL)
0.53
SpO2 on admission, Median (IQR) 88(85-89)% 89(84-92)% 90(86-92)% 0.08
Oxygen treatment duration , Median (IQR) 12(6-22)days 7(0-13)days 9(0-22)days 0.29
GCV treatment duration , Median (IQR) * 13 (9-17)days 14(10-17)days 8(7-10) days 0.013*
Percentage of the patients with low IgG (IgG < 176 mg/dl)* 20% 33% 33% 0.02*
Percentage of the patients with low CD4 (CD4 < 35%)* 81% 56% 50% 0.001*
*p < 0.05 IQR Interquartile range.
Table 3 Number of white blood cell (WBC), the
































*The values were shown as means +/- standard deviations.



























Figure 2 Cytomegalovirus (CMV) viral load and the course of
ganciclovir (GCV) treatment. After 1-week treatment with GCV,
CMV viral load reduced significantly (p < 0.05). The values are shown
as means +/- standard deviations.
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[10,18]. The CMV-DNA copy number in plasma indi-
cated the amount of free CMV-DNA circulating in the
bloodstream. Active CMV replication is considered use-
ful in monitoring the clinical course of CMV infections
[10]. However, CMV-DNA copy number in tracheal as-
pirates indicated the total amount of free CMV-DNA
and CMV-DNA in cells detached from the respiratory
airway. In this study, high copy numbers of CMV-DNA
were detected both in plasma and in the tracheal
aspirates of each patient, which suggested that CMV
replicated actively in the lungs of the patients and
caused pneumonia.
GCV reduced CMV-DNA promptly in the plasma to
below the detection limit, improving respiratory symp-
toms and chest X-ray images, which indicated the effi-
cacy of GCV in this study. The effectiveness of GCV in
the treatment of CMV infection has been reported in
other series [2,3,7,19]. In our study, 97.7% had a good
response to GCV therapy. There was one death (2.3%),
in a patient with dual infection with Burkholderia
cepacia. Capulong et al. reported that the mortality rate
directly due to CMV pneumonia was 50% after renal
transplantation [2], which was much higher than the rate
in our study.
Our results also showed that GCV treatment is safe
for severe CMV-associated pneumonia in children.
Though GCV liver toxicity has been reported to be very
severe [20], it was mild and temporal in our study. As
shown in Table 3, liver enzymes increased slightly
and transiently after GCV treatment. Renal function
remained normal during treatment. Our results are dif-
ferent from reports using GCV in immunocompromised
adult patients, where toxicity is frequently encountered,
with manifestations of myelosuppression, hematologic
abnormalities (primarily neutropenia, anemia, and
thrombocytopenia), infusion site reactions, gastro-
intestinal abnormalities and central nervous system ab-
normalities [19,20]. Only one patient suffered from
severe anemia with a Hb level less than 8 g/dL after
the first week of antiviral treatment, which required
red blood cell transfusion. We did not find any major
toxicity associated with GCV treatment.
Conclusions
From our results, we conclude that GCV is effective and
safe in the treatment of severe CMV-associated pneumo-
nia in children. However, a randomized clinical trial
would be necessary to obtain a more conclusive recom-
mendation for GCV treatment in CMV-associated pneu-
monia in children.
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